The ITP Impact Survey (I-WISh) is a collaborative investigation among global ITP experts, patient support groups and Novartis Pharmaceuticals Corporation.

The purpose of this cross-sectional global survey is to analyse and report the real-world impact of immune thrombocytopenia (ITP) on patients’ quality of life, management of the condition, and opinions toward treatment.

I-WISh is the largest observational global survey ever conducted in ITP including 1,400 ITP patients and 480 health care providers who treat the condition from the following 14 countries: Canada, China, Colombia, Egypt, France, Germany, Italy, India, Japan, Norway, Spain, Turkey, United Kingdom, and United States.

For more information watch the video below and visit GlobalITP.org.

Source: GlobalITP.org